Overview

A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension

Status:
Withdrawn
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
To define the relationship between Cardene I.V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
Facet Biotech
Treatments:
Nicardipine